"如果初中时有人告诉我，长痘不是忍忍就好，我现在额头就不会留着像小火山口一样的疤。"小刘对着镜子，指尖轻轻划过额角的瘢痕，语气里藏着跨越 十余年的遗憾。 痤疮，俗称青春痘。在中国，很多青少年会被告知：青春痘没啥，忍忍就好。但一份流行病学研究表明：95%的人会有不同程度痤疮发生，3%~7%痤疮 患者会遗留疤痕。 不少人囿于青春期的敏感心理，会为"面子"自卑，也有人会因为这道疤痕，影响到职业发展。 近期，葡萄妈开始调整葡萄的饮食，停了饮料、冰淇淋，控制糖分摄入，也让她每天用祛痘洁面，偶尔敷面膜、涂防晒，医生说青春期激素影响大，现在 就得好好护着。 她常会跟葡萄聊起长痘的事，孩子知道长痘不好看，也怕以后越来越严重、留疤，跟她一样焦虑。跑了好多医院和机构，都是治标不治本，反反复复的， 真怕影响她以后的心态。 洋洋（大二男生）：脸颊的硬结，困住了青春的自信 "13岁开始长痘，以为是青春期正常现象，没想到一发不可收拾，脸颊两侧和下巴全是，有些还成了硬结。"大二男生洋洋摸了摸脸颊，语气里满是无奈。 最初长痘，身边人都说等过了青春期就好，他没当回事，直到痘痘越来越多，才慌了。他去过医院，抹过各种药膏，效果都不明显，现在定期针 ...

"地尼法司他(ASC40)是痤疮治疗领域的创新性疗法，具有潜在的临床重要意义。我们非常荣幸能在本 届EADV年会上向皮肤病学界展示这些结果。"歌礼创始人、董事会主席兼首席执行官吴劲梓博士表 示，"地尼法司他(ASC40)采用痤疮治疗新作用机制，在III期研究中所有主要和次要终点较安慰剂均显 示出高度具有统计学意义且临床意义显著的改善，同时显示出良好的安全性和耐受性特征。" 歌礼正与中国国家药品监督管理局(NMPA)进行地尼法司他(ASC40)的上市申请前(Pre-NDA)沟通， NMPA目前反馈良好。歌礼计划在完成上市申请前沟通后向NMPA提交地尼法司他(ASC40)用于治疗中 重度寻常性痤疮的新药上市申请 (NDA)。 智通财经APP讯，歌礼制药-B(01672)发布公告，在2025年9月17日于法国巴黎举行的2025年欧洲皮肤病 与性病学会(EADV)年会最新突破性研究专场上口头报告了地尼法司他(denifanstat，ASC40)治疗中重度 寻常性痤疮的III期研究 (NCT06192264)结果。 歌礼已从Sagimet Biosciences Inc.(纳斯达克股票代码：SGMT)获得地尼法司他 ( ...

Core Viewpoint - The company reported significant revenue growth and advancements in its drug pipeline, particularly in obesity treatment, indicating strong research and development capabilities and a commitment to addressing unmet clinical needs [1][2]. Financial Performance - Total revenue reached RMB 104 million, representing a year-on-year increase of 111.4% [1] - Research and development costs amounted to RMB 147 million, up 10.9% year-on-year [1] - Loss attributable to equity shareholders was RMB 87.95 million, a decrease of 32.5% compared to the previous year [1] - Loss per share was 9.14 cents [1] Drug Development Progress - ASC30, an oral medication for obesity, showed a significant average weight reduction of 6.5% after 28 days in a U.S. Phase Ib study, positioning it as a potential best-in-class treatment for obesity [1] - The company rapidly enrolled 125 participants in a U.S. Phase IIa study for ASC30, demonstrating efficient execution in clinical trials [2] - ASC30 also showed a 36-day half-life in a single subcutaneous injection study, supporting less frequent dosing [2] - ASC47, another obesity treatment, exhibited a 40-day half-life and has completed participant enrollment for a study combining it with semaglutide [2] - ASC50, an oral IL-17 inhibitor, has entered Phase I clinical trials with initial dosing completed [2] - ASC40, a daily oral FASN inhibitor for acne treatment, demonstrated statistically significant improvements in all primary and secondary endpoints in a Phase III study, indicating its potential for a breakthrough in acne treatment [2] Research and Development Commitment - The achievements highlight the company's strong R&D capabilities and commitment to developing best-in-class and first-in-class drugs to meet long-term clinical needs [2]

Core Viewpoint - Acne is a common issue faced by adolescents, particularly during the summer months when high temperatures and humidity can exacerbate the condition. Experts suggest that while mild acne can often resolve with daily care, moderate to severe cases should be treated promptly to prevent long-term skin damage and psychological effects [1][2]. Group 1: Causes and Mechanisms - Acne is a chronic inflammatory skin disease affecting the pilosebaceous unit, primarily seen in adolescents due to increased androgen levels and sebum production [1]. - Factors contributing to acne include excessive keratinization of hair follicles, bacterial infections, hormonal imbalances, immune factors, psychological stress, chemical irritants, and genetic predisposition [1]. - Lifestyle factors such as smoking, alcohol consumption, medication use, and inappropriate cosmetic choices can also trigger acne outbreaks [1]. Group 2: Treatment Recommendations - For mild acne, daily care such as using gentle cleansers, avoiding irritating skincare products, not squeezing pimples, and maintaining a balanced diet and regular sleep schedule is recommended [2]. - Moderate to severe acne, if untreated, can lead to scarring and impact mental health and social interactions, necessitating professional medical intervention [2]. - Acne typically improves with age as hormone levels stabilize, but moderate to severe cases may require targeted treatment strategies as self-resolution is less likely [2].